Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. SMS Pharmaceuticals Limited
483
•SMS Pharmaceuticals Limited•March 21, 2025

FDA 483 - SMS Pharmaceuticals Limited - March 21, 2025

View on Dashboard

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Record Details

An FDA inspection of SMS Pharmaceuticals Limited, an API Non-Sterile Drug Substance Manufacturer in Bachupally, India, identified a significant deficiency related to employee training. The firm failed to ensure that Quality Control laboratory reviewers were adequately trained and qualified to review laboratory data for drug product release, as evidenced by specific instances involving assay and residual solvents testing.

Company
SMS Pharmaceuticals Limited
Inspection Date
March 21, 2025
Product Type
Drugs
Office
Office of Biological Products Operations - Division I
Person
  • Ankur C. Patel
Open in Dashboard

ID · c7467f98-2056-4d22-a7da-beb60f631ee0

footer
Global Key Solutions
Regulatory Data Transformed
Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@globalkeysolutions.net
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026, Global Key Solutions All rights reserved.